Tuberculosis (TB)-associated immune reconstitution inflammatory syndrome in TB-HIV co-infected patients in Malaysia: prevalence, risk factors, and treatment outcomes

被引:4
|
作者
Tan, Hong Yien [1 ]
Yong, Yean Kong [1 ]
Lim, Sin How [1 ]
Ponnampalavanar, Sasheela [1 ,2 ]
Omar, Sharifah F. S. [1 ,2 ]
Pang, Yong Kek [1 ,3 ]
Kamarulzaman, Adeeba [1 ,2 ]
Price, Patricia [7 ]
Crowe, Suzanne M. [4 ,5 ,6 ]
French, Martyn A. [7 ,8 ]
机构
[1] Univ Malaya, Fac Med, Ctr Excellence Res AIDS CERiA, Kuala Lumpur 50603, Malaysia
[2] Univ Malaya, Med Ctr, Dept Med, Infect Dis Unit, Kuala Lumpur 50603, Malaysia
[3] Univ Malaya, Med Ctr, Dept Med, Resp Unit, Kuala Lumpur 50603, Malaysia
[4] Macfarlane Burnet Inst Med Res & Publ Hlth, Ctr Biomed Res, Melbourne, Vic 3004, Australia
[5] Alfred Hosp, Infect Dis Unit, Melbourne, Vic 3004, Australia
[6] Monash Univ, Dept Infect Dis, Clayton, Vic 3800, Australia
[7] Univ Western Australia, Sch Pathol & Lab Med, Translat Immunol Unit, Perth, WA 6000, Australia
[8] Royal Perth Hosp, Dept Clin Immunol, Perth, WA 6000, Australia
基金
英国医学研究理事会;
关键词
antiretroviral therapy; antituberculosis treatment; ANTIRETROVIRAL THERAPY; MYCOBACTERIUM-TUBERCULOSIS; INITIATION; RESPONSES; DISEASE; UNMASKING; ANTIGENS; IRIS; AIDS;
D O I
10.1071/SH14093
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is an important early complication of antiretroviral therapy (ART) in countries with high rates of endemic TB, but data from South-East Asia are incomplete. Identification of prevalence, risk factors and treatment outcomes of TB-IRIS in Malaysia was sought. Methods: A 3-year retrospective study was conducted among TB-HIV co-infected patients treated at the University of Malaya Medical Centre. Simple and adjusted logistic regressions were used to identify the predictors for TB-IRIS while Cox regression was used to assess the influence of TB-IRIS on long-term CD4 T-cell recovery. Results: One hundred and fifty-three TB-HIV patients were enrolled, of whom 106 had received both anti-TB treatment (ATT) and ART. The median (IQR) baseline CD4 T-cell count was 52 cells mu L-1 (13-130 cells mu L-1). Nine of 96 patients (9.4%) developed paradoxical TB-IRIS and eight developed unmasking TB-IRIS, at a median (IQR) time of 27 (12-64) and 19 (14-65) days, respectively. In adjusted logistic regression analysis, only disseminated TB was predictive of TB-IRIS [OR: 10.7 (95% CI: 1.2-94.3), P = 0.032]. Mortality rates were similar for TB-IRIS (n = 1, 5.9%) and nonTB- IRIS (n = 5, 5.7%) patients and CD4 T-cell recovery post-ART was not different between the two groups (P = 0.363). Conclusion: Disseminated TB was a strong independent predictor of TB-IRIS in Malaysian HIV-TB patients after commencing ART. This finding underscores the role of a high pathogen load in the pathogenesis of TB-IRIS; so interventions that reduce pathogen load before ART may benefit HIV patients with disseminated TB.
引用
收藏
页码:532 / 539
页数:8
相关论文
共 50 条
  • [41] Predictors of mortality among TB-HIV Co-infected patients being treated for tuberculosis in Northwest Ethiopia: a retrospective cohort study
    Balewgizie Sileshi
    Negussie Deyessa
    Belaineh Girma
    Muluken Melese
    Pedro Suarez
    BMC Infectious Diseases, 13
  • [42] Treatment Outcome of Tuberculosis and Associated Factors among TB-HIV Co-Infected Patients at Public Hospitals of Harar Town, Eastern Ethiopia. A five-year retrospective study
    Tola, Assefa
    Mishore, Kirubel Minsamo
    Ayele, Yohanes
    Mekuria, Abraham Nigussie
    Legese, Nanati
    BMC PUBLIC HEALTH, 2019, 19 (01)
  • [43] Treatment Outcome of Tuberculosis and Associated Factors among TB-HIV Co-Infected Patients at Public Hospitals of Harar Town, Eastern Ethiopia. A five-year retrospective study
    Assefa Tola
    Kirubel Minsamo Mishore
    Yohanes Ayele
    Abraham Nigussie Mekuria
    Nanati Legese
    BMC Public Health, 19
  • [44] Non-adherence to anti-TB drugs among TB/HIV co-infected patients in Mbarara Hospital Uganda: Prevalence and associated factors
    Amuha, Monica G.
    Kutyabami, Paul
    Kitutu, Freddy E.
    Odoi-Adome, Richard
    Kalyango, Joan N.
    AFRICAN HEALTH SCIENCES, 2009, 9 : S8 - S15
  • [45] Treatment outcome and its attributes in TB-HIV co-infected patients registered under Revised National TB Control Program: a retrospective cohort analysis
    Ambadekar, N. N.
    Zodpey, S. P.
    Soni, R. N.
    Lanjewar, S. P.
    PUBLIC HEALTH, 2015, 129 (06) : 783 - 789
  • [46] What is the best strategy for treating TB-HIV co-infected patients with HAART and rifampicin without saquinavir?
    Torres, Thiago S.
    Rolla, Valeria C.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2007, 11 (08) : 933 - 934
  • [47] Factors associated with tuberculosis treatment delay in patients co-infected with HIV in a high prevalence area in Brazil
    Nogueira, Betania M. F.
    Rolla, Valeria C.
    Akrami, Kevan M.
    Kiene, Susan M.
    PLOS ONE, 2018, 13 (04):
  • [48] Complement-driven inflammasome activation on circulating blood monocytes in immune reconstitution inflammatory syndrome in TB-HIV coinfected patients
    Lage, Silvia Lucena
    Wong, Chun-Shu
    Hsu, Denise C.
    Sturdevant, Daniel
    Manion, Maura
    Naqvi, Nuha S.
    Lisco, Andrea
    Laidlaw, Elizabeth
    Mejia, Yolanda
    Amaral, Eduardo Pinheiro
    Sereti, Irini
    JOURNAL OF IMMUNOLOGY, 2020, 204 (01):
  • [49] MULTIDRUG RESISTANT TUBERCULOSIS IN TB/HIV CO-INFECTED PATIENTS IN RIVERS STATE, NIGERIA
    Alex-Wele, Mary
    Onyejepu, Nneka
    Obunge, Orikomaba
    SEXUALLY TRANSMITTED INFECTIONS, 2019, 95 : A129 - A129
  • [50] Tuberculosis treatment outcomes of diabetic and non-diabetic TB/HIV co-infected patients: A nationwide observational study in Brazil
    Villalva-Serra, Klauss
    Barreto-Duarte, Beatriz
    Nunes, Vanessa M.
    Menezes, Rodrigo C.
    Rodrigues, Moreno M. S.
    Queiroz, Artur T. L.
    Arriaga, Maria B.
    Cordeiro-Santos, Marcelo
    Kritski, Afranio L.
    Sterling, Timothy R.
    Araujo-Pereira, Mariana
    Andrade, Bruno B.
    FRONTIERS IN MEDICINE, 2022, 9